Clinical Trial Update: A Study to Compare the Effectiveness and Safety of IBI310 Combined With Sintilimab Versus Sorafenib in the First-line Treatment of Advanced HCC [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing IBI310 plus Sintilimab versus Sorafenib as first-line treatment for advanced hepatocellular carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• IBI310 (IBI310)
• Sintilimab (sintilimab)
• Sorafenib (Sorafenib)

Snippet

Sponsor: Innovent Biologics (Suzhou) Co. Ltd. | Conditions: Hepatocellular Carcinoma | Phase 3 | Status: COMPLETED